Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Publication | Open Access

DOI Full Paper Access

128

Citations

References

2020

Year

Chloe Orkin, Edwin DeJesus, Paul E. Sax, José Ramón Arribas, Samir K. Gupta, Claudia Martorell, Jeffrey L. Stephens, Hans‐Jürgen Stellbrink, David A. Wohl, Franco Maggiolo,

The Lancet HIV

Abstract

References